Existing companion diagnostics to select patients eligible for anti-CD70 therapy include ex vivo assessment of CD70 expression in solid and hematological tumors by immunohistochemistry and flow cytometry, respectively (Flieswasser et al. 2019; Leupin et al. 2022). This evidence concerns the gene CD70 and hematopoietic and lymphoid cell neoplasm.